홈 > 시장보고서 > 의약품 > 처방약

시장보고서

상품코드

2143386

조직구증 치료 시장 : 치료법별, 질환별, 최종사용자별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)

Histiocytosis Treatment Market, By Treatment Type, By Disease Type, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033

발행일: 2026년 09월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 337 Pages | 배송안내 : 2-3일 (영업일 기준)

가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 3,250

￦ 4,396,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,560

￦ 6,169,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650

￦ 7,643,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

조직구증 치료 시장 규모는 2025년에 26억 170만 달러로 평가되며, 2026년부터 2033년까지 CAGR 7.6%로 확대될 것으로 전망됩니다.

조직구증 치료는 조직구의 비정상적인 축적, 그리고 혈구포식성 림프조직구증(HLH), 랑게르한스 세포 조직구증(LCH), 로자이-돌프만병(RDD) 등의 질환으로 인한 염증 및 장기 손상의 관리에 중점을 둔 치료 분야입니다. 치료법 결정은 일률적이지 않습니다. 이는 조직구증의 아형, 어느 장기가 침범되었는지, 환자의 연령, 질환의 중증도, 그리고 해당 병세가 신규 진단인지, 치료에 반응하지 않는지, 혹은 재발한 것인지 등에 크게 좌우됩니다. 이러한 복잡성으로 인해 치료 선택지는 매우 다양합니다. 여기에는 화학요법, 면역조절제, MAPK 경로를 억제하는 표적 치료, 수술, 그리고 국소 방사선 치료가 포함됩니다.

미국 국립암연구소(NCI)의 2025년 1월 치료 지침 개정판에서는 LCH(조직구증)의 치료법으로 수술, 방사선 치료, 전신 요법이 제시되어 있습니다. 최신 연구에서는 분자 검사에 기반한 치료가 점점 더 중요시되고 있습니다. 이러한 변화는 광범위한 접근 방식에서 생물학에 기반한 정밀 치료법으로 전환되는 이 분야의 동향을 반영합니다. 시장 상황도 이에 따라 진화하고 있으며, 희귀질환이라는 전문성이 높은 분야에서 맞춤형 치료 전략에 대한 관심이 높아지고 있습니다.

조직구증 치료 시장 - 시장 역학

MAPK 경로의 변이를 분자 수준에서 규명

이 시장에서 치료의 특정 촉진요인은 조직구 질환 치료법을 선택할 때 분자 수준에서의 특성 평가의 중요성이 높아지고 있다는 점입니다. LCH 및 일부 관련 조직구증에서는 RAS/MAPK/ERK 경로의 활성화 변화가 관찰되므로, 의사는 화학요법에 그치지 않고 BRAF 및 MEK 억제제를 사용할 수 있습니다. 2025년 리뷰에서는 MAPK 활성화가 특징 중 하나라고 언급된 반면, 조직구 질환은 희귀하며 병태에 큰 편차가 있기 때문에 여전히 맞춤형 치료가 필요하다고 강조되고 있습니다. 그 결과, 의사는 돌연변이 검사를 실시하고 분자 분류를 수행하여, 치료 가능한 특정 돌연변이에 맞춰 치료법을 결정해야 합니다. 이러한 변화로 인해 치료 시장에서의 경쟁은 더 이상 세포독성 요법의 제공에 그치지 않고, 특정 유전자 프로파일을 가진 환자에서 효능을 입증하고, 일반적인 BRAF 변이를 가지고 있지 않은 환자를 위한 의약품을 개발하는 방향으로 전환되고 있습니다.

조직구증 치료 시장 - 세분화 분석:

세계 조직구증 치료 시장은 치료 유형, 질환 유형, 최종사용자 및 지역을 기준으로 세분화되어 있습니다.

치료법 유형별로 살펴보면, 조직구증의 치료법 선택은 1차 치료법인지 2차 치료법인지 여부보다 질환의 생물학적 특성이나 체내 발생 부위에 따라 크게 좌우됩니다. 병변이 국소적인 경우에는 수술이나 방사선 치료가 적절한 선택지가 될 수 있습니다. 병변이 체내 여러 부위로 퍼져 있거나 치료에 반응하지 않는 경우에는 보다 광범위한 접근이 필요합니다. 화학요법은 특히 질환을 제어하기 위한 확립된 방법이 있는 경우에 중요합니다. 또한, MAPK를 매개로 하는 질환 등 질환의 구성요소에 대한 과학적 지식이 깊어짐에 따라 표적 치료의 중요성도 높아지고 있습니다. 면역요법은 면역계의 과잉 반응을 억제하는 것을 주요 목적으로 하는 과염증성 HLH에서 중요한 역할을 하고 있습니다. 2025년 중국에서 여러 병원이 참여한 연구에서는 개선이 보이지 않거나 재발한 LCH 소아 환자에 대한 클로팔라빈의 유효성이 검토되었습니다. 이 조사는 7개 기관에서 수행되었으며, 이러한 증례에 대한 화학요법 연구가 현재도 진행 중임을 보여줍니다. 치료법의 분류는 단순히 대체 가능한 선택지라기보다는, 질환을 치료하는 방법과 그 적용 시나리오를 나타냅니다.

질환의 종류에 따라 필요한 치료법은 다릅니다. HLH, LCH, RDD는 체내에서 어떻게 작용하는지, 환자에게 어떤 증상이 나타나는지, 그리고 치료 목표가 무엇인지라는 점에서 크게 다르기 때문입니다. HLH는 주로 면역계의 통제 불가능한 반응이 문제이므로, 면역계를 억제하기 위한 신속한 개입이 필요하며, 그 후 원인을 치료하는 경우가 있습니다. LCH의 치료는 질환의 진행 정도에 따라 국소 치료부터 전신 요법까지 다양합니다. RDD의 치료에는 또 다른 전략이 사용되며, 어떤 장기가 침범되었는지, 그리고 유전자 프로파일에서 무엇이 확인되었는지에 따라 경과 관찰, 면역계 조절, 화학요법, 혹은 표적 치료가 선택될 수 있습니다. 중국 의학회가 발표한 성인 LCH에 관한 2025년 합의문에서는 MAPK 경로의 활성화가 특징으로 명확히 제시되어 있으며, 구체적인 치료 지침이 제시되어 있습니다. 따라서 질환의 분류에 따라 적용되는 치료법이 직접 결정되며, 획일적인 접근 방식은 피하게 됩니다.

조직구증 치료 시장 -- 지역별 인사이트

북미는 희귀질환 연구 인프라, 규제 활동, 전문 치료 센터, 그리고 표적 치료에 대한 접근성이 결합되어 있다는 점에서 중요한 지역입니다. 미국 식품의약국(FDA)은 2025년 6월, 에마팔맙의 적응증을 확대하여 글루코코르티코이드를 내약할 수 없는 경우나 질환이 재발한 경우, 알려진 또는 의심되는 스틸병에 수반되는 HLH/대식세포 활성화 증후군을 가진 성인 및 소아 환자를 대상으로 포함시켰습니다. 이러한 규제 변경으로 인해 확립된 조직구증을 대상으로 하는 생물학적 제제의 사용 범위가 확대되었으며, 이는 적응증 확대 및 신약 출시를 통해 치료 시장이 어떻게 발전할 수 있는지를 보여줍니다. 따라서 북미는 표적 치료 및 면역 지향적 접근법의 유효성을 검증하고, 전문적인 임상 연구를 규제된 치료 경로로 전환하기 위한 환경으로 계속 자리 잡고 있습니다.

중국은 전문가들의 합의 형성, 희귀질환 조사, 그리고 기존 치료법과 표적 치료법 모두에 관한 임상 연구를 통해 그 역할을 확립해 왔습니다. 2025년 5월, 중국 의학회 혈액 희귀질환 학술 그룹과 중국 LCH 네트워크는 진단, 치료 및 반응 평가에 관한 성인 LCH에 대한 최신 합의안을 발표했습니다. 같은 해, 난치성 또는 재발성 LCH 소아 환자를 대상으로 한 클로팔라빈에 관한 임상시험이 등록되어, 중국의 전문 네트워크 내에서 구제 화학요법이 적극적으로 연구되고 있음을 보여주었습니다. 따라서 중국의 지역적 중요성은 치료의 범위를 넘어섰으며, 그 임상 연구 생태계는 분자 수준에서 특징이 규명된 LCH 및 치료가 어려운 질환에 대한 치료 전략에 대해 현지에서 얻은 근거를 제공하고 있습니다.

Histiocytosis treatment is a disease therapeutic area that focuses on managing the abnormal buildup of histiocytes and the inflammation or organ damage that can result from conditions like hemophagocytic lymphohistiocytosis (HLH), Langerhans cell histiocytosis (LCH), and Rosai-Dorfman disease (RDD). Deciding on a treatment is not one-size-fits-all. It depends heavily on the subtype of histiocytosis, which organs are involved, the patient's age, the severity of the disease, and whether the condition is newly diagnosed, not responding to treatment, or has recurred. Because of this complexity, treatment options vary widely. They include chemotherapy, immunomodulatory agents, targeted therapies that block the MAPK pathway, surgery, and localized radiation.

The National Cancer Institute's January 2025 treatment update lists surgery, radiation, and systemic medicines as part of LCH care. Newer research increasingly emphasizes treatment guided by molecular testing. This shift reflects a trend in the field-moving from broad approaches to precise, biology-driven therapies. The market is evolving accordingly, with a growing focus on personalized treatment strategies within a specialized rare-disease landscape.

Histiocytosis Treatment Market- Market Dynamics

Molecular identification of MAPK- pathway alterations

The market-specific driver for treatment is the growing importance of molecular characterization when choosing therapy for histiocytic disorders. LCH and several related histiocytoses have activating changes in the RAS/MAPK/ERK pathway, so doctors can go beyond chemotherapy and use BRAF and MEK inhibitors. A review from 2025 states that MAPK activation is a feature, but it also stresses that care still needs to be personalized because histiocytic disorders are rare and vary significantly. As a result, doctors need to perform mutation testing, do molecular classification, and match therapies to the specific changes that can be treated. This shift means that competition in the treatment market is no longer about offering cytotoxic regimens; instead, it is about demonstrating effectiveness in patients with defined genetic profiles and creating medicines for those who do not have common BRAF changes.

Histiocytosis Treatment Market- Segmentation Analysis:

The Global Histiocytosis Treatment Market is segmented on the basis of Treatment Type, Disease Type, End User, and Region.

By treatment type, the choice for histiocytosis is more influenced by the biology of the disease and where it is located in the body than by a first-line versus second-line approach. When there are localized areas of disease, surgery or radiation might be the right choice. When the disease is in multiple parts of the body or does not respond to treatment, a broader approach is needed. Chemotherapy is important, especially when there are established ways to control the disease. Targeted therapy is also becoming more important as scientists learn more about the components of the disease, like MAPK-driven disease. Immunotherapy plays a role in hyperinflammatory HLH, where stopping the immune system from overreacting is a main goal. A 2025 study in China involving hospitals looked at clofarabine for children with LCH that did not improve or recurred. This study was conducted at seven sites, showing that research into chemotherapy for these cases is still ongoing. The way the treatment is split shows methods to treat the disease and where they are used rather than options that can be swapped easily.

By disease type, the kind of disease affects the treatment needed because HLH, LCH, and RDD are very different in how they operate in the body, how they present in patients, and what the treatment goals are. HLH is mostly about the system acting out of control and might need rapid intervention to reduce the immune system and then treat the cause. LCH treatment can range from localized treatments to full-body therapy, depending on how far the disease has spread. RDD brings in another strategy for treatment, where observation, adjusting the immune system, chemotherapy, or targeted therapy might be used, depending on which organs are involved and what is identified in the genetic profile. A 2025 agreement for adult LCH from the Chinese Medical Association clearly lists MAPK-pathway activation as a feature and provides specific treatment advice. Therefore, the classification of the disease directly determines what treatment is used and prevents a one-size-fits-all approach.

Histiocytosis Treatment Market- Geographical Insights

North America is significant due to its combination of rare-disease research infrastructure, regulatory activity, specialist treatment centers, and access to targeted therapies. The U.S. FDA expanded the labeled use of emapalumab in June 2025 to include adults and pediatric patients with HLH/macrophage activation syndrome associated with known or suspected Still's disease when glucocorticoids are not tolerated or when the disease recurs. This regulatory change broadens the settings in which an established histiocytosis-directed biologic can be used and shows how treatment market development can happen through indication expansion as well as new drug launches. North America, therefore, remains an environment for validating targeted and immune-directed approaches and translating specialist clinical research into regulated treatment pathways.

China has developed a role through specialist consensus development, rare-disease research, and clinical investigation of both conventional and targeted therapies. In May 2025, the Chinese Medical Association's Hematological Rare Disease Academic Group and China LCH Network released an updated adult LCH consensus addressing diagnosis, treatment, and response evaluation. The same year also saw the registration of a clofarabine study for children with refractory or relapsed LCH, showing active investigation of salvage chemotherapy within the country's specialist network. China's regional significance, therefore, extends beyond treatment; its clinical research ecosystem is contributing locally generated evidence on molecularly characterized LCH and treatment strategies for difficult-to-treat diseases.

Histiocytosis Treatment Market- Competitive Landscape:

Competition is increasingly organized around mechanisms, molecular selectivity, and evidence generation rather than a broad oncology portfolio alone. Roche/Genentech's cobimetinib has an FDA-approved indication for adult neoplasms, while research programs are extending MEK inhibition into refractory LCH and other histiocytic disorders. Day One's tovorafenib is also being investigated in relapsed or refractory LCH, reflecting interest in RAF-pathway inhibition for molecularly defined disease. Meanwhile, established chemotherapy and immunomodulatory approaches remain useful because histiocytosis encompasses different disorders, and not every patient is suited to a targeted agent. The unique advantage is, consequently, the ability to demonstrate lasting disease control within defined molecular or clinical subgroups while maintaining an acceptable treatment load.

Recent Developments:

In June 2025, the FDA widened the use of emapalumab so that it can treat HLH or macrophage activation syndrome in people who have known or suspected HLH. The new label applies to adults and children, including newborns and older kids, if they do not receive enough help from glucocorticoids or if they keep having MAS again.

In September 2025, the NACHO-COBI study continued looking for patients with refractory LCH and other histiocytic disorders to test cobimetinib. The Phase II program has four groups covering refractory LCH, LCH that causes neurodegenerative disease, and other histiocytic disorders.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HISTIOCYTOSIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Sanofi S.A.
Swedish Orphan Biovitrum (SOBI)
AB2 Bio Ltd.
Pfizer Inc.
Novartis AG
F. Hoffmann-La Roche Ltd (Roche)
Johnson & Johnson Services
Incyte Corporation
Merck & Co., Inc.
Eli Lilly and Company
Bristol-Myers Squibb Company
Amgen Inc.
Blueprint Medicines
Genentech
Alpine Immune Sciences
Nippon Shinyaku Co., Ltd.
Fresenius Kabi AG
Others

GLOBAL HISTIOCYTOSIS TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020 - 2033

Radiation Therapy
Chemotherapy
Targeted Therapy
Immunotherapy
Surgery
Others

GLOBAL HISTIOCYTOSIS TREATMENT MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2020 - 2033

Hemophagocytic Lymphohistiocytosis
Langerhans Cell Histiocytosis
Rosai-Dorfman Disease
Others

GLOBAL HISTIOCYTOSIS TREATMENT MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

Ambulatory Surgical Centers
Hospitals
Specialty Clinics
Others

GLOBAL HISTIOCYTOSIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Denmark
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Taiwan
Vietnam
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Iran
Qatar
Rest of MEA

1. Histiocytosis Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Histiocytosis Treatment Market Snippet by Treatment Type
- 2.1.2. Histiocytosis Treatment Market Snippet by Disease Type
- 2.1.3. Histiocytosis Treatment Market Snippet by End User
- 2.1.4. Histiocytosis Treatment Market Snippet by Country
- 2.1.5. Histiocytosis Treatment Market Snippet by Region
2.2. Competitive Insights

3. Histiocytosis Treatment Key Market Trends

3.1. Histiocytosis Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Histiocytosis Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Histiocytosis Treatment Market Opportunities
3.4. Histiocytosis Treatment Market Future Trends

4. Histiocytosis Treatment Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Histiocytosis Treatment Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Histiocytosis Treatment Market Landscape

6.1. Histiocytosis Treatment Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Histiocytosis Treatment Market - By Treatment Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
- 7.1.2. Radiation Therapy
- 7.1.3. Chemotherapy
- 7.1.4. Targeted Therapy
- 7.1.5. Immunotherapy
- 7.1.6. Surgery
- 7.1.7. Others

8. Histiocytosis Treatment Market - By Disease Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Disease Type, 2025 & 2033 (%)
- 8.1.2. Hemophagocytic Lymphohistiocytosis
- 8.1.3. Langerhans Cell Histiocytosis
- 8.1.4. Rosai-Dorfman Disease
- 8.1.5. Others

9. Histiocytosis Treatment Market - By End User

9.1. Overview
- 9.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
- 9.1.2. Ambulatory Surgical Centers
- 9.1.3. Hospitals
- 9.1.4. Specialty Clinics
- 9.1.5. Others

10. Histiocytosis Treatment Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Histiocytosis Treatment Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Histiocytosis Treatment Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.8. UK
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.8.3. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.3.8.4. UK Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.3.8.5. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.9. France
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.9.3. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.3.9.4. France Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.3.9.5. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.10. Italy
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.10.3. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.3.10.4. Italy Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.3.10.5. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.11. Spain
  - 10.3.11.1. Overview
  - 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.11.3. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.3.11.4. Spain Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.3.11.5. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.12. The Netherlands
  - 10.3.12.1. Overview
  - 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.12.3. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.3.12.4. The Netherlands Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.3.12.5. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Overview
  - 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.3.13.5. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.14. Russia
  - 10.3.14.1. Overview
  - 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.14.3. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.3.14.4. Russia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.3.14.5. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.15. Poland
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.15.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.3.15.4. Poland Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.3.15.5. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.16. Denmark
  - 10.3.16.1. Overview
  - 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.16.3. Denmark Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.3.16.4. Denmark Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.3.16.5. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.3.17. Rest of Europe
  - 10.3.17.1. Overview
  - 10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.3.17.4. Rest of the Europe Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.3.17.5. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Histiocytosis Treatment Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.7. China
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.7.3. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.4.7.4. China Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.4.7.5. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.8. India
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.8.3. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.4.8.4. India Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.4.8.5. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.12. Indonesia
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.12.3. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.4.12.4. Indonesia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.4.12.5. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.13. Thailand
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.13.3. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.4.13.4. Thailand Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.4.13.5. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.15. Taiwan
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.15.3. Taiwan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.4.15.4. Taiwan Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.4.15.5. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.16. Vietnam
  - 10.4.16.1. Overview
  - 10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.16.3. Vietnam Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.4.16.4. Vietnam Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.4.16.5. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.4.17. Rest of APAC
  - 10.4.17.1. Overview
  - 10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.4.17.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.4.17.4. Rest of APAC Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.4.17.5. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Histiocytosis Treatment Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Histiocytosis Treatment Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.8. UAE
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.8.3. UAE Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.6.8.4. UAE Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.6.8.5. UAE Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.13. Iran
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.13.3. Iran Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.6.13.4. Iran Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.6.13.5. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.14. Qatar
  - 10.6.14.1. Overview
  - 10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.14.3. Qatar Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.6.14.4. Qatar Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.6.14.5. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 10.6.15. Rest of MEA
  - 10.6.15.1. Overview
  - 10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 10.6.15.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  - 10.6.15.4. Rest of MEA Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  - 10.6.15.5. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

11. Key Vendor Analysis- Histiocytosis Treatment Industry

11.1. Competitive Benchmarking
- 11.1.1. Competitive Dashboard
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. Sanofi S.A.
- 11.2.2. Swedish Orphan Biovitrum (SOBI)
- 11.2.3. AB2 Bio Ltd.
- 11.2.4. Pfizer Inc.
- 11.2.5. Novartis AG
- 11.2.6. F. Hoffmann-La Roche Ltd (Roche)
- 11.2.7. Johnson & Johnson Services
- 11.2.8. Incyte Corporation
- 11.2.9. Merck & Co., Inc.
- 11.2.10. Eli Lilly and Company
- 11.2.11. Bristol-Myers Squibb Company
- 11.2.12. Amgen Inc.
- 11.2.13. Blueprint Medicines
- 11.2.14. Genentech
- 11.2.15. Alpine Immune Sciences
- 11.2.16. Others

12. 360 Degree AnalystView

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격